Rhythm Pharmaceuticals Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Rhythm Pharmaceuticals Inc.
Former names: Rhythm Metabolic, INC.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: Boston
Headquarters state / province: Massachusetts
Headquarters country: United States
Fiscal year end: December
Ticker symbol: RYTM
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001649904
EIN: 46-2159271
Wikidata ID: Q30269284

Board of directors

Follow this board

Camille L. Bedrosian · Director
Since 2023
Christophe Jean · Director
Since 2023
David P. Meeker · Director · President and CEO
Since 2023
David W. J. Mcgirr · Director
Since 2023
Edward T. Mathers · Director Overboarded
Since 2023
Jennifer L. Good · Director
Since 2023
Kimberly J. Popovits · Director
Since 2026
Lynn A. Tetrault · Director
Since 2023
Stuart A. Arbuckle · Director
Since 2023

Chief executives

David P. Meeker · President and CEO

Dates unknown

Director election results

Annual meeting of June 24, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

David W. J. Mcgirr

85.9%
David P. Meeker

96.9%

Board connections

7 of this board's directors also sit on 14 other boards. 12 are in the same sector.

Shared director Other board Same sector

Trevi Therapeutics Inc. Same sector
via David P. Meeker, Edward T. Mathers and Jennifer L. Good
Kardigan Inc. Same sector
via David P. Meeker and Kimberly J. Popovits
10x Genomics Inc.
via Kimberly J. Popovits
Alnylam Pharmaceuticals Inc. Same sector
via Stuart A. Arbuckle
Alumis Inc. Same sector
via Lynn A. Tetrault
Insmed Incorporated Same sector
via David W. J. Mcgirr
Kiniksa Pharmaceuticals International plc Same sector
via Kimberly J. Popovits
MBX Biosciences Inc. Same sector
via Edward T. Mathers
NeoGenomics Inc.
via Lynn A. Tetrault
OnKure Therapeutics Inc. Same sector
via Edward T. Mathers
Pharvaris N.V. Same sector
via David P. Meeker
Praxis Precision Medicines Inc. Same sector
via Stuart A. Arbuckle
Senti Biosciences Holdings Inc. Same sector
via Edward T. Mathers
X4 Pharmaceuticals Inc. Same sector
via David W. J. Mcgirr

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $36,379,846; 48 sales by 9 insiders

Date	Insider	Transaction	Shares	Price	Value
Sep 14, 2026	David P. Meeker Director, Officer (President and CEO)	Option exercise	+50,000	$6.05	$302,500
Sep 14, 2026	David P. Meeker Director, Officer (President and CEO)	Open-market sale	−6,439	$101.75	$655,168
Sep 14, 2026	David P. Meeker Director, Officer (President and CEO)	Open-market sale	−30,746	$102.35	$3,146,853
Sep 14, 2026	David P. Meeker Director, Officer (President and CEO)	Open-market sale	−8,698	$103.43	$899,634
Sep 14, 2026	David P. Meeker Director, Officer (President and CEO)	Open-market sale	−1,817	$104.55	$189,967
Sep 14, 2026	David P. Meeker Director, Officer (President and CEO)	Open-market sale	−2,300	$105.19	$241,937
Aug 31, 2026	Hunter C. Smith Officer (Chief Financial Officer)	Option exercise	+57,187	$25.79	$1,474,853
Aug 31, 2026	Hunter C. Smith Officer (Chief Financial Officer)	Open-market sale	−23,072	$104.59	$2,413,100
Aug 31, 2026	Hunter C. Smith Officer (Chief Financial Officer)	Open-market sale	−11,514	$105.37	$1,213,230
Aug 31, 2026	Hunter C. Smith Officer (Chief Financial Officer)	Open-market sale	−28,188	$106.20	$2,993,566
Aug 13, 2026	Lee Jennifer Kayden Officer (EVP, Head of North America)	Option exercise	+35,000	$24.29	$850,150
Aug 13, 2026	Garfield Alastair Officer (Chief Scientific Officer)	Open-market sale	−2,007	$116.11	$233,033
Aug 13, 2026	Shulman Joseph Officer (Chief Technical Officer)	Option exercise	+2,024	$6.80	$13,763
Aug 13, 2026	Lee Jennifer Kayden Officer (EVP, Head of North America)	Option exercise	+21,601	$6.80	$146,887
Aug 13, 2026	Garfield Alastair Officer (Chief Scientific Officer)	Open-market sale	−1,556	$117.08	$182,176

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Rhythm Pharmaceuticals Inc.

Who is the CEO of Rhythm Pharmaceuticals Inc.?

David P. Meeker is Rhythm Pharmaceuticals Inc.'s President and CEO.

How many directors are on Rhythm Pharmaceuticals Inc.'s board?

Rhythm Pharmaceuticals Inc.'s board has 9 directors: Camille L. Bedrosian, Christophe Jean, David P. Meeker, David W. J. Mcgirr, Edward T. Mathers, Jennifer L. Good, Kimberly J. Popovits, Lynn A. Tetrault and Stuart A. Arbuckle.

Are Rhythm Pharmaceuticals Inc. insiders buying or selling shares?

Over the last 12 months, Rhythm Pharmaceuticals Inc. insiders made no open-market purchases and sold $36.4 million of shares in 48 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Rhythm Pharmaceuticals Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="rhythm-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.